They enrolled 280
patients in a trial that compared the standard eflornithine regimen with one
in which only 14 infusions of that drug were
given over a week's time, combined with 10 days of nifurtimox, an oral drug licensed against Chagas disease — which is also caused by Trypanosoma
parasites — but not considered active enough as a standalone HAT drug.